Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model

R. Scott Rector,1,2,3 Grace M. Uptergrove,1 E. Matthew Morris,1,3 Sarah J. Borengasser,3 M. Harold Laughlin,5 Frank W. Booth,4,5,6 John P. Thyfault,1,2,3 and Jamal A. Ibdah1,2,3,4

1Division of Gastroenterology and Hepatology, 2Harry S. Truman Memorial Veterans Medical Center, Departments of 3Nutrition and Exercise Physiology, 4Medical Pharmacology and Physiology, 5Biomedical Sciences, and 6Daltone Cardiovascular Research Center, University of Missouri, Columbia, Missouri

Submitted 15 November 2010; accepted in final form 22 February 2011

POOR DIETARY CHOICES AND SEDENTARY lifestyles are leading to a weight gain epidemic in Westernized societies. A critical complication of the obesity epidemic is the development of type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). NAFLD affects ~30% of all U.S. adults and 75–100% of obese and morbidly obese individuals (3, 5) and is now considered the hepatic representation of the metabolic syndrome (10).

Caloric restriction and exercise are commonly recommended for prevention and amelioration of obesity and lifestyle-related diseases such as NAFLD (6). Recent investigations suggest that being habitually more physically active (32), doing higher amounts of physical activity during leisure time (50), and routinely performing or increasing ones physical activity levels by ≥150 min/wk (43) is inversely associated with NAFLD. Having higher cardiorespiratory fitness also is inversely associated with NAFLD and nonalcoholic steatohepatitis (NASH) (8, 21). Furthermore, maintenance of normal body weight is associated with lower incidence of NAFLD (5). In addition, interventions aimed at lowering body weight by caloric restriction alone or in combination with exercise significantly lower intrahepatic fat content in obese adults (41) and improves liver histology in biopsy-proven NASH patients (35). Unfortunately, studies to date have not directly compared the effects and mechanistic differences between weight loss induced by exercise vs. weight loss induced by caloric restriction on development of NAFLD.

We have recently characterized the development of NAFLD in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat. Selectively bred for null expression of the cholecystokinin-1 receptor, OLETF rats exhibit a within-meal feedback defect for satiety, resulting in hyperphagia, obesity, and insulin resistance and type 2 diabetes (18, 26). OLETF rats also develop hepatic steatosis at a young age, with a progression to hepatocyte ballooning and increased fibrosis and collagen deposition by 40 wk of age in a progressive pattern similar to the human disease (36–38). However, unlike most obese animal models (45), the OLETF rat will exercise voluntarily on running wheels, which we have shown to attenuate the development of NAFLD (36, 37). While NAFLD prevention with exercise was associated with increased hepatic fatty acid oxidation and reduced hepatic lipogenesis in these animals, daily exercise also attenuated weight gain (36, 37), suggesting that the observed protective effects may be due in part to an attenuation in adiposity.

Recently, it has been suggested that, because of the absence of an effective drug therapy, lifestyle modifications aimed at arresting NAFLD development and progression should be made in younger individuals (29). Here we directly compared the effectiveness of daily exercise vs. daily caloric restriction on the prevention of obesity and NAFLD in the OLETF rat. We also sought to determine whether daily exercise has additional benefits beyond weight reduction achieved by caloric restriction alone. In addition, the design allowed us to compare
and contrast the mechanisms by which each therapy prevents NAFLD. We hypothesized that both preventative therapies would attenuate NAFLD, but with a greater upregulation in hepatic mitochondrial content and function in the exercising OLETF rats.

METHODS

Animal protocol. The animal protocol was approved by the Institutional Animal Care and Use Committee at the University of Missouri-Columbia. Male OLETF rats at 4 wk of age were kindly supplied by the Tokushima Research Institute, Otsuka Pharmaceutical (Tokushima, Japan) and upon arrival were randomly assigned to either sedentary cage conditions with ad libitum feeding (OLETF-SED), sedentary cage conditions with food intake adjusted to 70% of food intake by the OLETF-SED animals studied in parallel (OLETF-EX; 70% pair feeding), or immediately housed in cages equipped with voluntary running wheels (OLETF-EX) outfitted with a Sigma Sport BC 606 bicycle computer (Cherry Creek Cyclery, Foster Falls, VA) for measuring daily running activity. Nonhyperphagic, control strain Long-Evans Tokushima Otsuka (LETO) rats were kept in the sedentary cage conditions for the duration of the study (LETO-SED). All animals were individually caged throughout the entire experiment. Cages were in temperature-controlled animal quarters (21°C) with a 0600–1800 light and 1800–0600 dark cycle. The OLETF-SED, OLETF-EX, and LETO-SED animals were provided standard rodent chow (Formulab 5008; Purina Mills, St. Louis, MO) for ad libitum feeding in new cages at the beginning of each week. Standard rodent chow also was provided to the OLETF-EX animals daily based on ~70% of the satiated OLETF-SED rat food consumption, an amount equal to the volume of food consumed by the LETO control animals, as previously reported (23). Body mass was measured weekly throughout the investigation. OLETF-EX animals were given free access to voluntary running wheels 24 h/day, and the daily running activity was obtained between 0800 and 1000 each morning. OLETF-EX and LETO-SED rats also had ad libitum access to food and water until the designated time of death (40 wk of age). At 40 wk of age, rats were anesthetized with pentobarbital sodium (100 mg/kg) and then exsanguinated by removal of the heart 5 h after locking of wheels; the sedentary rats (OLETF-SED, OLETF-CR, and LETO-SED) were killed at the same time. All animals were fasted for 5 h before death.

Dual-energy x-ray absorptiometry. Whole-body composition was measured using a Hologic QDR-1000w dual-energy X-ray absorptiometry machine calibrated for rats as previously described (23).

Tissue homogenization procedure and fatty acid oxidation. Livers were quickly excised from anesthetized rats and either flash-frozen in liquid nitrogen, placed in 10% formalin, or placed in ice-cold isolation buffer (in mM: 100 KCl, 40 Tris-HCl, 10 Tris-Base, 5 MgCl2·6H2O, 1 EDTA, and 1 ATP; pH 7.4). Palmitate oxidation was measured with radiolabeled [1-14C]palmitate (American Radiochemicals) in fresh liver homogenate preparations as previously reported (37). Lignocerate oxidation (a very-long-chain fatty acid, C-22) was measured with radiolabeled [1-14C]lignocerate (American Radiochemicals) in fresh liver homogenate preparations as previously described (30) as an index to assess peroxisomal fatty acid oxidation. Both 14CO2, representing complete fatty acid oxidation, and 14C-labeled acid soluble metabolites, representing incomplete fatty acid oxidation, were collected and counted as previously described (37). Palmitate oxidation experiments were performed in the presence (100 μM) or absence of etomoxir [a specific inhibitor of mitochondrial carnitine palmitoyl-CoA transferase (CPT)-1 and entry into the mitochondrial] to examine the relative contribution of mitochondrial (−etomoxir) and extramitochondrial organelles (+etomoxir) in total fatty acid oxidation.

Intrahepatic lipid content, Oil-Red O staining, and liver histology. Intrahepatic triglyceride (TG) content was determined as previously described (37). Hepatic diacylglycerol (DAG) content was determined by using a modified Folch (11) method. Briefly, liver tissue was homogenized in ice-cold Trizma-EDTA buffer, and lipids were extracted in chloroform-methanol-acetic acid (2:1:0.15). Extracted lipids were then run on a thin-layer chromatography silica plate in a tank containing hexane, diethylether, and acetic acid (70:30:1). DAG fractions were scraped and methylated by incubating with toluene, methanol, and acetyl chloride (0.5:1:2.01) at 100°C for 60 min and separated in hexane. Fatty acid methyl esters were analyzed by GC (Agilent Technologies). Oil-Red O staining was performed in frozen liver sections as previously described (37). To examine liver morphology, formalin-fixed paraffin-embedded sections of liver were stained with hematoxylin and eosin (H&E). For assessment of hepatic steatosis, histopathological criteria proposed by Kleiner et al. (19) were adopted in five to six animals per group and three views per animal. Hepatic steatosis was graded as follows: 5% (score 0), 5%-33% (score 1), >33%-66% (score 2), or >66% (score 3). Sirius red staining for collagen deposition was performed as previously referenced (38, 49).

Western blotting. Western blot analyses were performed for the determination of AMPKα1, AMPKα2 Thr172 phosphorylation-specific, acetyl-coenzyme A carboxylase (ACC), ACC Ser79 phosphorylation-specific, fatty acid synthase (FAS) (Cell Signaling, Beverly, MA), stearoyl-CoA desaturase-1 (SCD-1; Alpha Diagnostics International, San Antonio, TX), peroxisome proliferator-activated receptor-α (PPARα; Santa Cruz Biotechnology, Santa Cruz, CA), peroxisome proliferator-activated receptor-γ (PPARγ; Santa Cruz Biotechnology), acyl-CoA oxidase 1 (ACOX1; Santa Cruz Biotechnology), cytochrome P-450 A2 (CYP4A; Abcam, Cambridge, MA), sterol regulatory element binding protein 1c (SREBP-1c; Santa Cruz Biotechnology), mammalian target of rapamycin (mTOR; Cell Signaling), phos-
pho-mTOR Ser2448 (Cell Signaling), and oxidative phosphorylation (OXPHOS) complexes I to V of the electron transport chain (MitoProfile Total OXPHOS Rodent WB Antibody Cocktail; MitoSciences, Eugene, OR). Content of phosphoproteins (using phosphospecific antibodies) was calculated from the density of the band of the phosphoprotein divided by the density of the protein (total) using the appropriate antibody (36, 37). To control for equal protein loading and transfer, the membranes were stained with 0.1% amido black (Sigma) as previously described (37). The total protein staining for each lane was quantified, and these values were used to correct for any differences in protein loading or transfer of all band densities.

**Fat pad collection and serum assays.** Retroperitoneal and omental fat pads were removed from exsanguinated animals and weighed. Serum glucose (Sigma, St. Louis, MO), TG (Sigma), free fatty acids (FFA; Wako Chemicals, Richmond, VA), and insulin (Linco Research, St. Charles, MO) were measured using commercially available kits according to the manufacturer’s instructions after a 12-h overnight fast and 12-h wheel lock in the OLETF-EX rats. This 12-h overnight fast occurred at 38–39 wk of age and coincided with the glucose tolerance test (described below). Serum alanine aminotransferase (ALT) and hemoglobin A\textsubscript{1c} (HbA\textsubscript{1c}) concentrations were measured as previously described (23, 37).

**Intraperitoneal glucose tolerance test.** Intraperitoneal glucose tolerance tests (IPGTTs) were performed at 38–39 wk of age (n = 6/group). Food was removed from the cages 12 h before each received an intraperitoneal injection of dextrose (50% solution, 2 g/kg body wt). The running wheels in the OLETF-EX rats were locked 12 h before the IPGTT procedure began. Venipuncture blood samples were collected from the lateral tail vein immediately before (0 min) dextrose administration and 15, 30, 45, 60, and 120 min after injection. After centrifugation at 4°C at 80°C until glucose and insulin measurement by a glucose oxidase kit (Thermo Electron, Louisville, CO) and ELISA (Millipore, Billerica, MA), respectively. Insulin sensitivity was estimated as the product of the areas under the curve (AUCs) for glucose and insulin calculated using the trapezoidal method (46).

**Reduced and oxidized glutathione.** Reduced (GSH) and oxidized (GSSG) glutathione concentrations were determined by a fluorometric method as previously described by our group (38).

**Superoxide dismutase, catalase, citrate synthase, β-hydroxyacyl-CoA dehydrogenase, and glutathione reductase activity.** Superoxide dismutase (SOD) activity in liver homogenates was determined by commercially available methods (Cayman Chemicals, Ann Arbor, MI). Catalase activity was determined by commercially available

### Table 1. Animal and liver characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>LETO-SED</th>
<th>OLETF-SED</th>
<th>OLETF-EX</th>
<th>OLETF-CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body fat, %</td>
<td>20.0 ± 1.0\textsuperscript a</td>
<td>31.6 ± 3.3\textsuperscript b</td>
<td>14.0 ± 1.2\textsuperscript a</td>
<td>19.1 ± 1.7\textsuperscript a</td>
</tr>
<tr>
<td>Fat pad mass, g</td>
<td>11.9 ± 0.7\textsuperscript a</td>
<td>54.4 ± 6.3\textsuperscript b</td>
<td>10.8 ± 1.6\textsuperscript a</td>
<td>15.7 ± 1.6\textsuperscript a</td>
</tr>
<tr>
<td>Serum glucose, mg/dl</td>
<td>98.5 ± 5.9\textsuperscript a</td>
<td>169.0 ± 9.4\textsuperscript b</td>
<td>104.7 ± 4.6\textsuperscript a</td>
<td>121.3 ± 5.4\textsuperscript a</td>
</tr>
<tr>
<td>Serum insulin, ng/ml</td>
<td>1.93 ± 0.28\textsuperscript a</td>
<td>3.13 ± 0.97\textsuperscript b, c</td>
<td>1.48 ± 0.46\textsuperscript a</td>
<td>3.9 ± 0.49\textsuperscript b</td>
</tr>
<tr>
<td>HOMA (ratio)</td>
<td>83.3 ± 14.0\textsuperscript a</td>
<td>216.8 ± 61.8\textsuperscript b</td>
<td>59.1 ± 24.1\textsuperscript a</td>
<td>211.1 ± 33.0\textsuperscript b</td>
</tr>
<tr>
<td>HbA\textsubscript{1c}, %</td>
<td>4.6 ± 0.04\textsuperscript a</td>
<td>7.9 ± 0.8\textsuperscript b</td>
<td>4.4 ± 0.1\textsuperscript a</td>
<td>4.3 ± 0.01\textsuperscript a</td>
</tr>
<tr>
<td>Serum TG, mg/dl</td>
<td>42.8 ± 4.4\textsuperscript b</td>
<td>237.4 ± 45.8\textsuperscript b</td>
<td>51.5 ± 7.3\textsuperscript a</td>
<td>66.3 ± 4.0\textsuperscript a</td>
</tr>
<tr>
<td>Serum ALTs, U/l</td>
<td>54.9 ± 2.5</td>
<td>69.3 ± 11.2</td>
<td>64.9 ± 6.5</td>
<td>52.8 ± 5.6</td>
</tr>
<tr>
<td>Heart wt-to-body wt ratio, mg/g</td>
<td>2.54 ± 0.06\textsuperscript a</td>
<td>2.42 ± 0.12\textsuperscript a</td>
<td>3.19 ± 0.11\textsuperscript b</td>
<td>2.62 ± 0.06\textsuperscript a</td>
</tr>
</tbody>
</table>

Values are means ± SE; n = 6–8 rats in each group. Fat pad mass was the combination of omental and retroperitoneal fat pads. LETO, Long-Evans Tokushima Otsuka; SED, sedentary; OLETF, Otsuka Long-Evans Tokushima fatty; EX, exercised; CR, calorie restricted; TG, triglycerides; ALT, alanine aminotransferase. Homeostasis model assessment (HOMA) = (pmol/l insulin × mmol/l glucose)/22.5 Ref (46). Values with different superscripts are significantly different (P < 0.01).
methods (Sigma) as previously described (47). Citrate synthase and β-hydroxyacyl-CoA dehydrogenase (β-HAD) activities were determined in whole liver homogenate using the methods of Srere et al. (42) and Bass et al. (2), respectively, as previously described (36, 37). Glutathione reductase activity was assessed by commercially available kits (Cayman Chemicals).

Statistics. Each outcome measure was examined in six to eight animals. For each outcome measure, a one-way ANOVA was performed (SPSS/15.0; SPSS, Chicago, IL). Significant main effects \( P < 0.05 \) were followed up with Fisher least-significant difference post hoc comparisons. Values are reported as means ± SE, and a \( P \) value \(< 0.05 \) denotes a statistically significant difference.

RESULTS

Animal characteristics. Similar to our previous reports (23, 27), OLETF-EX animals displayed initial running distances of \(~4 \text{ km/day} (~150 \text{ min/day}) \) at 4 wk of age and \(~12 \text{ km/day} (~275 \text{ min/day}) \) at 10 wk of age, then declining to \(~7 \text{ km/day} (~200 \text{ min/day}) \) at 20 wk of age and \(~4 \text{ km/day} (~150 \text{ min/day}) \) by 40 wk of age (data not shown). By design, absolute food consumption of the OLETF-CR animals was \(~70\% \) of OLETF-SED and equal to the amount consumed by LETO-SED animals, and ad libitum food consumption was similar between OLETF-SED and OLETF-EX (Fig. 1A). Caloric restriction and daily wheel running resulted in significantly lower body weights in the OLETF-CR and OLETF-EX rats compared with OLETF-SED (70% of OLETF-SED values; \( P < 0.001 \); final body weights are shown in Fig. 1B, inset), which were equal to LETO-SED values. Voluntary running and caloric restriction suppressed fat pad mass (omental and retroperitoneal) and percent body fat gain compared with OLETF-SED (\( P < 0.01 \)) to the level of the LETO-SED (Table 1). OLETF-EX animals also displayed a higher heart weight-to-body weight ratio, indicating that adequate stimulus to produce training adaptations was achieved (Table 1).

Fasting glucose was significantly lower in the LETO-SED, OLETF-EX, and OLETF-CR rats compared with OLETF-SED, with LETO-SED and OLETF-EX concentrations also being significantly lower than OLETF-CR (Table 1). OLETF-EX and LETO-SED animals also exhibited significantly lower fasting serum insulin and HOMA calculations (24) compared with OLETF-CR and OLETF-SED animals (Table 1). The lack of differences between OLETF-SED and OLETF-CR and LETO-SED is because of the development of frank type 2 diabetes and a loss of normal pancreatic insulin secretion in the 40-wk-

![Fig. 3. Representative images of hematoxylin and eosin (H&E) (×10 and 40 fields of view; A and B), Oil-Red O (C), and picrosirius red (D) staining. Note the large lipid vacuoles (A and B), macro- and microvesicular steatosis (A-C), hepatocyte ballooning and nuclear displacement (A and B), and perivenular fibrosis (C) in the 40-wk-old OLETF-SED animals compared with the other animal groups.](http://ajpgi.physiology.org/ by 10.220.33.6 on April 4, 2017)
old OLETF-SED rats, as we have previously reported (23). This is supported by the observation of OLETF-SED animals having twofold higher HbA1c levels compared with other groups ($P < 0.001$; Table 1). In addition, serum TG levels were significantly elevated in the OLETF-SED animals compared with other groups ($P < 0.01$; Table 1).

Glucose tolerance. Glucose and insulin responses to an IPGTT are shown in Fig. 2. Glucose AUC was significantly greater in OLETF-SED compared with OLETF-EX and LETO-SED ($P < 0.01$; Fig. 2, A and B) and tended to be greater compared with OLETF-CR ($P = 0.1$). In addition, glucose AUC was reduced to a greater extent in the OLETF-EX compared with LETO-SED (Fig. 2, A and B). Insulin responses to the IPGTT did not differ among LETO-SED, OLETF-SED, and OLETF-CR but were significantly lower in the OLETF-EX compared with LETO-SED and OLETF-CR ($P < 0.05$; Fig. 2, C and D). Insulin AUCs are significantly elevated in the OLETF-SED compared with LETO-SED, OLETF-EX, and OLETF-EX at 20 wk of age but drop fivefold from 20 to 40 wk in the OLETF-SED animals (data not shown).

Liver antioxidative status. Liver SOD activity was higher in the OLETF-EX and OLETF-CR rats compared with OLETF-SED ($P < 0.01$; OLETF-SED = 4.11 ± 0.47 U/ml, OLETF-EX = 5.81 ± 0.68, OLETF-CR = 6.78 ± 0.46), whereas catalase activity was lower in OLETF-EX than OLETF-SED and OLETF-CR ($P < 0.05$; OLETF-SED = 1.65 ± 0.11 μM·μg⁻¹·min⁻¹, OLETF-EX = 1.31 ± 0.06, OLETF-CR = 1.54 ± 0.08). In addition, glutathione reductase activity was significantly reduced in the OLETF-EX compared with OLETF-SED ($P < 0.05$) and tended to be reduced in OLETF-CR compared with OLETF-SED ($P = 0.07$; OLETF-SED = 2.58 ± 0.17 nmol/μg/min, OLETF-EX = 2.13 ± 0.10, OLETF-CR = 2.27 ± 0.05). Furthermore, the GSH-to-GSSG ratio was greater in the OLETF-EX compared with OLETF-SED and OLETF-CR ($P < 0.01$; OLETF-SED = 41.1 ± 6.5, OLETF-EX = 24.9 ± 2.10, OLETF-CR = 26.4 ± 1.7).

Daily exercise and caloric restriction attenuate NAFLD progression in OLETF rats. Representative images of randomly selected sections of the liver stained for H&E (both at $×10$ and $40$ magnification), Oil-Red O, and picrosirius red are shown in Fig. 3. OLETF-EX and OLETF-CR animals did not exhibit the significantly ($P < 0.001$) increased levels of macro- and microvesicular steatosis (Fig. 3, A–C), hepatocyte ballooning (Fig. 3B), or the increased fibrosis and collagen deposition in perivenular (around terminal hepatic veins) regions (Fig. 3D) that occurred at 40 wk in the OLETF-SED animals. Both preventative therapies normalized liver histological changes to that observed in the lean, LETO-SED controls. Liver injury was modest at this stage of development, since serum ALT levels did not differ among groups (Table 1). Biochemical analysis revealed significantly lower hepatic TG content in the OLETF-EX and OLETF-CR rats compared with OLETF-SED, with further attenuation in the OLETF-EX compared with OLETF-CR (Fig. 4A), to the level of the LETO-SED controls. In addition, steatosis scoring was significantly greater in the OLETF-SED animals compared with LETO-SED, OLETF-EX, or OLETF-CR rats ($P < 0.001$; Fig. 4B). Furthermore, DAG content was significantly lower in both intervention groups, with levels in OLETF-CR rats significantly lower than OLETF-EX animals ($P < 0.05$; Fig. 4C).
SED and LETO-SED animals (Fig. 5E). The lack of observed differences in β-HAD and citrate synthase activities between OLETF-SED and LETO-SED in whole liver homogenate in the current report differs from our previous findings in isolated hepatic mitochondria (38).

Impact of daily exercise and caloric restriction on markers of hepatic mitochondrial and extramitochondrial protein content. Hepatic CPT-1 protein content, the rate-limiting step in mitochondrial fatty acid entry, was significantly suppressed in the OLETF-SED rats compared with the other animal groups (P < 0.05; Fig. 6A). On the other hand, PPARα protein content was significantly elevated in the OLETF-SED animals (P < 0.05; Fig. 6B). However, PPARα-regulated proteins ACOX1 and CYP4A did not differ among groups (representative Western blot shown in Fig. 6C). Hepatic protein content for OXPHOS I, II, III, and V did not differ among groups; however, mitochondrial-encoded OXPHOS IV (subunit I) was significantly decreased in OLETF-SED animals but normalized to LETO-SED levels with daily EX (P < 0.05; Fig. 6D and E).

Impact of daily exercise and caloric restriction on markers of hepatic lipogenesis. Hepatic protein content of ACC and ACC Ser79 phosphorylation did not differ between LETO-SED and OLETF-SED but was significantly reduced in OLETF-EX animals (P < 0.05; Fig. 7A and B). However, hepatic FAS was significantly elevated in OLETF-SED animals and reduced with exercise and caloric restriction, with content being reduced to a greater extent in OLETF-EX animals (P < 0.05; Fig. 7C). On the other hand, phospho-mTOR and the active, mature form of SREBP-1c (68-kDa form) were both significantly elevated in the OLETF-CR animals compared with other animal groups (P < 0.01; Fig. 7, D and E). In addition, SCD-1 was significantly elevated in OLETF-SED and OLETF-CR rats compared with LETO-SED and OLETF-EX (P < 0.01; Fig. 7F). Hepatic protein content of AMPKα and AMPKα Thr172 phosphorylation did not differ among groups (data not shown), and hepatic PPARγ, SREBP-1c (125-kDa form), and total mTOR protein content did not differ among groups (representative Western blots shown in Fig. 7G).

DISCUSSION

The maintenance of normal body weight either through dietary modification or being habitually more physically active is associated with reduced incidence of NAFLD. In addition, weight control and exercise are commonly prescribed therapies for NAFLD (6, 14). In fact, being more physically active (32, 43, 50) or targeting weight loss by energy restriction alone or in combination with exercise training (33, 35, 41, 48) are associated with reduced NAFLD. However, a direct comparison between the effectiveness of preventing NAFLD by controlling body weight with caloric restriction alone or with exercise alone is lacking. Here we used the OLETF rat, a hyperphagic rodent model that develops obesity and NAFLD.

**Fig. 5. Effects of daily exercise and caloric restriction on hepatic complete palmitate oxidation to CO2 (A), total mitochondrial palmitate oxidation [CO2 and acid soluble metabolites (ASMs); B], total extramitochondrial palmitate oxidation (C), total lignocerate oxidation (CO2 and ASMs; D), β-hydroxyacyl-CoA dehydrogenase (β-HAD) activity (E), and citrate synthase activity (F). Values are means ± SE (n = 6–8). Values with different superscripts are significantly different (P < 0.05).**
to gain mechanistic insight into dietary and exercise preventative therapies targeting weight reduction. A novel, clinically relevant finding was that preventing weight gain with either daily exercise or daily caloric restriction effectively prevented NAFLD development seen in sedentary OLETF rats. However, despite similar hepatic phenotypes, OLETF rats that engaged in daily exercise also exhibited better systemic glucose tolerance; enhanced mitochondrial fatty acid oxidation, oxidative enzyme function, and protein content; and further suppression of hepatic de novo lipogenesis proteins compared with caloric restriction. This would collectively suggest distinct advantages of obesity prevention through daily exercise over caloric restriction in overall metabolic health.

NAFLD prevention through daily exercise was associated with an upregulation in hepatic mitochondrial fatty acid oxidation and a tighter coupling of β-oxidation and the tricarboxylic acid cycle, resulting in a more complete degradation of fatty acids compared with OLETF-SED and OLETF-CR animals. This occurred despite the fact that hepatic CPT-1, the rate-limiting step in mitochondrial fatty acid entry, was significantly elevated in both the OLETF-EX and OLETF-CR animals. Whether or not upregulated mitochondrial function and fatty acid oxidation has a beneficial impact on overall health has not been examined directly, but it previously has been demonstrated that overexpression of CPT-1 increases fatty acid oxidation and reduces hepatic TG accumulation (44). This documents that deficiencies in mitochondrial fatty acid entry and oxidative capacity play a role in NAFLD development.

In the current report, both daily exercise and caloric restriction independently reduce hepatic PPARα protein content and extramitochondrial fatty acid oxidation but did not alter hepatic ACOX1 and CYP4A protein content. Mitochondrial abnormalities are closely related to the pathogenesis of NAFLD (7, 16, 38, 40), and β-oxidative capacity is thought to be decreased (12, 31, 38) in NAFLD but not always in NASH (40). However, peroxisomal β-oxidation is elevated in the diabetic liver and in livers from fatty rats (1, 15). Our findings suggest that peroxisomal/microsomal activity, but not likely peroxisomal or microsomal content, is activated in the OLETF-SED animals to compensate for reduced mitochondrial content and function, which could lead to the accumulation of lipotoxic lipid moieties, factors known to activate hepatic mitochondrial oxidative stress (28). This would explain the compensatory increases in the GSH-to-GSSG ratio and glutathione reductase activity and the reduced SOD activity observed in the liver of the OLETF-SED rats.

Recent stable isotope tracer work demonstrates that ~26% of hepatic TG accumulation in NAFLD patients can be accounted for by de novo lipogenesis (9), highlighting the importance of this metabolic pathway in NAFLD. In addition, it has been implicated that, with the apparent uncoupling and reductions in complete mitochondrial fatty acid oxidation, incomplete oxidation products are likely being directed to fatty acid biosynthesis pathways (20, 28). Here, daily exercise globally impacted several measures of de novo fatty acid synthesis, including reduced ACC and FAS and increased...
phosphorylation of ACC (inactive when phosphorylated). In addition, daily exercise also dramatically reduced hepatic SCD-1 protein content compared with OLETF-SED rats. In combination with our previous report of reduced hepatic malonyl-CoA levels with exercise in OLETF rats (36), daily exercise appears to beneficially alter substrate partitioning and correct mitochondrial insufficiencies in this animal model.

Through the conversion of saturated fatty acids to monounsaturated fatty acids, hepatic SCD-1 contributes to abnormal partitioning of fatty acids by increasing ACC activity and decreasing fatty acid oxidation, shunting substrate toward fatty acid synthesis. There is also increasing evidence for a role of mTOR in inducing lipogenesis (22). The action of insulin on SCD-1-induced lipogenesis is thought to be mediated through regulation of mTOR and SREBP-1c (25), and the activation of lipogenesis and SREBP1c requires complex 1 of the target of rapamycin (34). Here we report that OLETF-CR animals exhibited significant increases in the active, mature form of SREBP-1c, increases in SCD-1, and increased catalytic activation of mTOR because of an increase in its phosphorylation status. This was independent of changes in PPARγ protein content. These findings suggest that, as opposed to the exercising animals that remained hyperphagic, the caloric-restricted animals have upregulated the machinery necessary for lipogenesis. These findings warrant future, more in-depth investigation.

Our findings suggest that daily exercise upregulates processes involved in hepatic mitochondrial flux and turnover to buffer the hypercaloric environment seen in this animal model, thereby oxidizing excess substrate, preventing de novo lipogenesis, and limiting hepatic TG and DAG accumulation that is seen in the hyperphagic, sedentary OLETF rat. Conversely, caloric restriction appears to prevent NAFLD not through enhanced mitochondrial flux but rather through elimination of hyperphagia and limiting available substrate to accumulate in the liver. An apparent balance between hepatic uptake, oxidation, and storage of fatty acids occurs under both preventative conditions but not in the OLETF-SED animals, whose hypercaloric status was not properly matched with an increase in mitochondrial β-oxidation, resulting in an increased need for extramitochondrial oxidative support and an excess accumulation of hepatic fat.

Our results document that both caloric restriction and daily exercise attenuate the loss of glycemic control and both prevent the type 2 diabetes development observed in the OLETF-SED rats, but with exercise being superior to caloric restriction despite similar reductions in body weight and adiposity between groups. Elevated release of FFAs from visceral adipose tissue into the portal circulation is thought to contribute to NAFLD and NASH (4). In the hyperphagic, sedentary, diabetic OLETF rat, insulin-mediated suppression of adipose tissue lipolysis is likely blunted, leading to an increased delivery of FFAs to the liver. Thus it is likely that reducing visceral adiposity and insulin resistance through daily exercise and caloric restriction had a significant impact on NAFLD in this rodent model.
An important consideration that still deserves attention is whether exercise training in the absence of weight loss can be used as an effective therapy in the prevention or treatment of NAFLD. A promising recent report suggests that short-term exercise training reduces hepatic lipid content in previously sedentary obese men and women in the absence of reductions in body weight or insulin resistance (17). These findings need to be confirmed in long-term exercise interventions.

In conclusion, our findings have important human health application, particularly for the 60–80% of Americans who overeat, who are overweight, and who are physically inactive. Our data support preventative strategies that either eliminate the overeating environment (OLETF-CR) or, if overeating is present, an increase in daily physical activity (OLETF-EX) to prevent obesity and NAFLD. In addition, daily exercise may offer health benefits beyond caloric restriction through better systemic glucose homeostasis and upregulation in hepatic mitochondrial function.

ACKNOWLEDGMENTS

The OLETF and LETO rats were a generous gift of the Tokushima Research Institute, Otsuka Pharmaceutical (Tokushima, Japan). We thank Suzie Ridenhour, Craig Meers, and Meghan Ruebel for excellent technical assistance. We also thank the Veterinary Medicine Diagnostics Laboratory at the University of Missouri for help with the histological sections and alanine aminotransferase measurements and the Diabetes Diagnostics Lab at the University of Missouri for help with the hemoglobin A1c measurements.

GRANTS

This work was supported with resources and the use of facilities at the Harry S. Truman Memorial Veterans Hospital in Columbia, MO. This work was partially supported by National Institutes of Health Grants DK-56345 (J. A. Ibda), HL-36088 (M. H. Laughlin), and F32 DK-83182 (R. S. Rector), and by institutional funds from the School of Medicine and College of Veterinary Medicine.

DISCLOSURES

No conflicts of interest are declared by the authors.

REFERENCES


AJP-Gastrointest Liver Physiol • VOL 300 • MAY 2011 • www.ajpgi.org
G883

EXERCISE VS. CALORIC RESTRICTION IN PREVENTION OF NAFLD


46. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17: 152–154, 1994.


